Welcome to our dedicated page for Revvity news (Ticker: RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity stock.
Revvity, Inc. reports developments for a global life sciences and diagnostics business that provides health science solutions, technologies, expertise and services across workflows from discovery and development to detection and diagnosis. Company updates center on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and Signals software for pharmaceutical, biotechnology, diagnostic laboratory, academic and government customers.
Recurring announcements include financial results and earnings calls, quarterly dividends, investor conference presentations, governance matters and product introductions. Recent product themes include Signals BioDesign for biologics construct design and research collaboration, Signals One platform integration, high-content imaging, multimode detection, sample preparation, screening and laboratory automation systems.
Revvity (NYSE: RVTY) unveiled multiple discovery platforms at SLAS2026 (Feb 7–11), including the Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation.
Highlights: improved camera quantum efficiency (60% to 95%), expanded AI image analysis, TRF/Alpha/luminescence sensitivity, 3–1000 µL liquid handling, and 21 CFR Part 11 compliance tools.
Revvity (NYSE: RVTY) reported Q4 2025 revenue of $772 million (6% growth) and GAAP EPS of $0.87. Adjusted EPS from continuing operations was $1.70. Full year 2025 revenue was $2.856 billion with GAAP EPS $2.07 and adjusted EPS $5.06. The company initiated 2026 guidance of $2.96–2.99 billion revenue and adjusted EPS $5.35–$5.45.
Revvity (NYSE: RVTY) announced a regular quarterly dividend of $0.07 per share on common stock, declared on January 26, 2026. The dividend is payable on May 8, 2026 to shareholders of record at the close of business on April 17, 2026. This provides a scheduled cash distribution to current shareholders on the stated record and payment dates.
Revvity (NYSE: RVTY) said it will release fourth-quarter and full-year 2025 results before market open on February 2, 2026 and will host a conference call at 8:00 a.m. ET. Preliminary Q4 2025 revenue is expected to be approximately $772 million with reported and organic growth of ~6% and ~4%, respectively. Full-year 2025 revenue is expected to be approximately $2,855 million with reported and organic growth of ~4% and ~3%. The company now expects full-year adjusted EPS to exceed the upper end of the prior $4.90–$5.00 guidance. The release notes use of non-GAAP measures and that adjusted EPS cannot be reconciled to GAAP without unreasonable effort.
Revvity (NYSE: RVTY) announced a collaboration with Eli Lilly to make Lilly TuneLab predictive models available through the Signals Xynthetica offering, creating a federated framework to accelerate AI-enabled drug discovery. The integration lets participating biotechs apply Lilly’s models inside the Signals platform while keeping proprietary data private via federated learning and Revvity’s Models-as-a-Service approach. Revvity’s Signals One and Signals Synergy modules provide data capture, analytics, and secure exchange to support the network. Lilly and Revvity will jointly fund access for selected participants, including software access and modeling credits, aimed at lowering barriers to AI adoption across the biotech ecosystem.
Revvity (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT. President and CEO Prahlad Singh will provide an update on the company and its strategic priorities. A live audio webcast will be available in the Events section of the company website, and a replay will be posted on the Revvity Investor Relations site and available for at least 30 days.
Revvity (NYSE: RVTY) announced Signals Xynthetica, a forthcoming AI Models-as-a-Service within the Revvity Signals platform that integrates in-silico molecular and materials design with experimental validation in a governed environment. The offering supports de novo generation, property prediction, and multi-objective optimization while enabling model governance, refreshes, and transparent evaluation alongside wet-lab results.
Revvity said pre-registration is open and early access programs begin in 1H 2026, positioning Signals Xynthetica as part of Revvity’s vision for AI-augmented discovery.
Revvity (NYSE: RVTY) entered into a definitive agreement to acquire ACD/Labs, a provider of scientific software for analytical characterization and molecular design. The transaction is expected to close late in Q4 2025. ACD/Labs products named in the announcement include Spectrus (spectral analysis), Percepta (AI molecular property and ADMET prediction), Katalyst D2D, Luminata, and ADMS.
The deal is positioned to expand Revvity Signals across discovery, development, scale-up, and manufacturing workflows and create a unified SaaS environment linking molecular design, analytical science, and quality control. Management noted customary forward-looking risks, including integration and market uncertainties.
Revvity (NYSE: RVTY) will present at three investor conferences in November–December 2025 with senior executives providing company updates and strategic priorities.
Schedule: UBS Global Healthcare Conference on Nov 10, 2025 at 8:00 a.m. ET (Max Krakowiak, SVP & CFO); Jefferies London Healthcare Conference on Nov 18, 2025 at 2:00 p.m. GMT (Max Krakowiak); and Citi Global Healthcare Conference on Dec 2, 2025 at 9:00 a.m. ET (Prahlad Singh, president & CEO).
Events are fireside chats; live audio webcasts will stream on the company Events page and replays will be posted to Revvity investor relations for at least 30 days.
Revvity (NYSE: RVTY) reported Q3 2025 results for the quarter ended September 28, 2025: revenue $699M (2% reported growth, 1% organic), GAAP EPS $0.40, and adjusted EPS $1.18. GAAP operating margin was 11.7%; adjusted operating margin was 26.1%. By segment, Life Sciences revenue was $343M (flat organic) and Diagnostics revenue was $356M (organic +2%).
The company reaffirmed 2025 organic growth guidance of 2%–4%, raised adjusted EPS guidance to $4.90–$5.00, and authorized a new $1 billion two-year share repurchase program. Management cited strategic partnerships and innovation as drivers for future execution.